The insulin market is undergoing a significant shift as global drugmakers prioritize GLP-1 and new generation insulins. In response to this trend, Biocon, Wockhardt, and Eris have announced plans to double their insulin production capacities. Wockhardt’s Managing Director, Murtaza Khorakiwala, highlighted the company’s strategic positioning to seize the emerging opportunities in the insulin market, with plans to expand capacities over the next 24 months.This move reflects the growing demand for insulin products and the need for companies to adapt to changing market dynamics. By increasing their production capabilities, Biocon, Wockhardt, and Eris are positioning themselves to cater to the evolving needs of patients worldwide. As the industry continues to focus on innovative insulin therapies, these companies are paving the way for future growth and sustainability in the insulin market.
Read more from moneycontrol.com
